A survey of physician knowledge & management of chronic hepatitis B infection and preferred methods of continuing education

Abstract

recurrent HCV, 2 patients had near-normalization of ALT and bilirubin within 1 year of initiation of therapy. One patient had gradual worsening of jaundice; one patient remained stable. Conclusions: 77% of patients treated for recurrent HCV became intolerant to IFN/ribavirin, stopping therapy after 9 to 330 days. However, treatment rapidly led to improvements in ALT and bilirubin in a majority of patients, including 2 of 4 patients with severe recurrent HCV. A sustained ALT response was achieved in 6 of 13 patients (46%), despite early discontinuation of IFN/ribavirin in one-half of these patients. We support the use of IFN/ribavirin in the treatment of recurrent HCV, in spite of medicationrelated side effects.

DOI: 10.1111/j.1572-0241.2000.02745.x

Cite this paper

@article{Burbige2000ASO, title={A survey of physician knowledge & management of chronic hepatitis B infection and preferred methods of continuing education}, author={Eugene J Burbige and Junko Takagi}, journal={American Journal of Gastroenterology}, year={2000}, volume={95}, pages={2523-2523} }